Agencies, 14 October: Wednesday te Glenmark Pharma para Nintedanib (NINDANIB) laga generic version, pulmonary fibrosis laga treatment nemide jola suru korise India te. Respiratory laga area te Glenmark toh ekta leader ase aro India te pulmonary fibrosis laga treatment suru kora first company hoise. Etu khobor toh regulatory filing te janaideya laga ase.
Aro koise, etu para patients ke besi cost-effective treatment option debo aro desh te doctors para besi patients ke treatment koribole para hobo.
Glenmark koise, Nintedanib toh Indian drug regulator para mana laga ase Idiopathic (unknown cause) Pulmonary Fibrosis (IPF) laga treatment nemide.
Company koise, “IPF toh progressive disease ase aro pura samai te beya hoi thakae. Joldi treatment suru kora aro treatment kori thaka toh bemari te komti koribole nemide kaam laga ase”.
Glenmark koise, tuita clinical trials toh Nintedanib te shaijabo nemide suru korise. Etu toh pulmonary fibrosis te COVID-19 pandemic toh moderate to severe COVID-19 patient te mela te sabo nemide suru korise.
Glenmark Group Vice President and Business Head, India Formulations Alok Malik koise, NINDANIB suru kora para ami khan India te patients nemide pill aro cost burden te manibo nemide biswas kori ase.
Add Comment